- Home
- VOR
as 11-21-2024 3:41pm EST
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 59.3M | IPO Year: | 2021 |
| Target Price: | $11.36 | AVG Volume (30 days): | 612.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $3.14 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Vor Biopharma Inc. News
VOR Breaking Stock News: Dive into VOR Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
GlobeNewswire
14 days ago
Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
MT Newswires
2 months ago
Vor Biopharma Names Han Choi as Chief Financial Officer
GlobeNewswire
2 months ago
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
MT Newswires
2 months ago
Sector Update: Health Care
MT Newswires
3 months ago
Vor Biopharma Reports Positive Trem-Cell Study Data; Shares Rise
GlobeNewswire
3 months ago
New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver Targeted Therapies
Simply Wall St.
3 months ago
Here's Why Vor Biopharma (NASDAQ:VOR) Must Use Its Cash Wisely
Compare VOR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VOR Vor Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.